Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telotristat etiprate - TerSera Therapeutics

X
Drug Profile

Telotristat etiprate - TerSera Therapeutics

Alternative Names: LP-778914; LX-1032; LX-1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; Xermelo

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Amines; Anti-inflammatories; Antineoplastics; Chlorobenzenes; Fluorinated hydrocarbons; Propionic acids; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant carcinoid syndrome
  • Phase II Neuroendocrine tumours
  • No development reported Cholangiocarcinoma; Colorectal cancer; Liposarcoma
  • Discontinued Biliary cancer; Ulcerative colitis

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for preclinical development in Cholangiocarcinoma in USA
  • 28 Aug 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
  • 28 Aug 2024 No recent reports of development identified for preclinical development in Liposarcoma in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top